Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
SWAV - ShockWave Medical Inc
-1.09(-0.83%)7:02:58 PM 1/22/2021
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.
Stock Chart


  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
  • A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
  • MACD is crossing MACD signal line at 1.6. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics


Related Peers

Stock news

    Shockwave Medical to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021

    SANTA CLARA, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Wednesday, February 17, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. In...

    Why ShockWave Medical Stock Jumped Today

    Shares of ShockWave Medical (NASDAQ: SWAV) were jumping 9.1% higher as of 3:47 p.m. EST after rising as much as 11.4% earlier in the day. Today's move appears to have possibly been fueled by institutional investors buying the stock. Often when this happens, it's the result of major institutional investors such as mutual funds, hedge funds, or pension funds scooping up large quantities of the stock.

    Is SWAV A Good Stock To Buy Now?

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

    Centers for Medicare & Medicaid Services Creates New Codes That Establish Specific Payment for Intravascular Lithotripsy Performed Below the Knee

    Four New C-Codes for IVL Performed Below the Knee in Hospital Outpatient SettingSANTA CLARA, Calif., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified peripheral and coronary artery disease, announced today that as part of the calendar year 2021 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule, the Centers for Medicare & Medicaid Servic...

    BofA Positive On Medtech Stock ShockWave In The Long Run

    Smid-cap MedTech company ShockWave Medical Inc (NASDAQ: SWAV) has seen its shares appreciate over 120% year-to-date.The ShockWave Analyst: BofA Securities analyst Bob Hopkins downgraded ShockWave from Buy to Neutral, citing valuation. Given the recent appreciation in the peer group, the analyst increased the price target to $105.Related Link: The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions The ShockWave Medical Thesis: BofA is very bull...

    Shockwave Medical to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

    SANTA CLARA, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference, scheduled to be held December 1 to 3, 2020. Shockwave's management is scheduled for a live fireside chat on Wednesday, December 2, 2020, at 8:30 a.m. Eastern Time. Interested part...

    ShockWave Medical Inc (SWAV) Q3 2020 Earnings Call Transcript

    Joining me today from ShockWave Medical are Doug Godshall, president and chief executive officer; Keith Dawkins, chief medical officer; and Dan Puckett, chief financial officer. Earlier today, ShockWave released financial results for the quarter ended September 30, 2020.

    Shockwave Medical (SWAV) Reports Q3 Loss, Tops Revenue Estimates

    Shockwave Medical (SWAV) delivered earnings and revenue surprises of 30.91% and 34.87%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?